Le Lézard
Classified in: Health, Science and technology

Global Biochips Markets to 2027 - Asia-Pacific to Offer Lucrative Growth Opportunities - ResearchAndMarkets.com


The "Global Biochips Market 2019-2027" report has been added to ResearchAndMarkets.com's offering.

The global biochips market is projected to progress with 19.32% of CAGR over the forecast period of 2019-2027.

The major driving factors in the global biochips market are the growth in personalized medicines, rising incidences & treatment of cancer, constant rise in worldwide healthcare spending and the increasing number of investments in biotechnology R&D.

Moreover, the development in biochips technology, and the widening application areas are the key opportunities nudging growth of the market towards the projected period.

However, challenges such as availability of substitute technologies, unclear regulatory guidelines and cost constraints are the factors restraining the biochips market growth.

Regional Outlook

Europe, Asia-Pacific, North America, and rest of the world are the four regional segments covered in the biochips market report.

North America biochips market leads the global scene by capturing the largest share in the year 2018. The market is driven by the increasing number of investments in biotechnology R&D and the increasing market demand for personalized medicine.

Over the forecasted period, the Asia-Pacific region will dominate the global biochips market in terms of CAGR.

Key Topics Covered

1. Biochips Market - Summary

2. Industry Outlook

2.1. Market Definition

2.2. Key Insights

2.3. Evolution & Transition of Biochips

2.4. Porter's Five Force Analysis

2.5. Market Attractiveness Matrix

2.6. Industry Components

2.7. Regulatory Framework

2.8. Vendor Scorecard

2.9. Key Impact Analysis

2.10. Market Opportunity Insights

2.11. Industry Player Positioning

2.12. Key Market Strategies

2.13. Market Drivers

2.13.1. Growth in Personalized Medicines

2.13.2. Rising Incidences & Treatment of Cancer

2.13.3. Constant Rise in Healthcare Spending Worldwide

2.13.4. Increasing Number of Investments in Biotechnology R&D

2.14. Market Restraints

2.14.1. Inequality in Healthcare Access

2.14.2. Inadequate Technical Awareness Related to Biochips

2.14.3. Complexity of Biological Systems

2.15. Market Opportunities

2.15.1. Developments in Biochips Technology

2.15.2. Asia-Pacific to Offer Lucrative Growth Opportunities

2.15.3. Widening Application Areas of Biochips

2.16. Market Challenges

2.16.1. Availability of Substitute Technologies

2.16.2. Unclear Regulatory Guidelines

2.16.3. Cost Constraints

3. Biochips Industry Outlook - By Type

3.1. DNA Chips

3.1.1. Agricultural Biotechnology

3.1.2. Cancer Diagnostics & Treatment

3.1.3. Drug Discovery

3.1.4. Gene Expression

3.1.5. Genomics

3.1.6. Single Nucleotide Polymorphism (SNP) Genotyping

3.1.7. Other DNA Chips

3.2. Lab On a Chip

3.2.1. Clinical Diagnostics

3.2.2. Drug Discovery

3.2.3. Genomics

3.2.4. Point of Care & in Vitro Diagnosis

3.2.5. Proteomics

3.2.6. Other Lab On a Chip

3.3. Protein Chips

3.3.1. Diagnostics

3.3.2. Drug Discovery

3.3.3. Expression Profiling

3.3.4. High Throughput Screening

3.3.5. Proteomics

3.3.6. Other Protein Chips

3.4. Other Chips

3.4.1. Cell Arrays

3.4.2. Tissue Arrays

4. Biochips Industry Outlook - By Substrate Material

4.1. Glass

4.2. Polymers

4.3. Silicon

4.4. Other Substrate Materials

5. Biochips Industry Outlook - By End User

5.1. Biotechnology and Pharmaceutical Companies

5.2. Hospitals and Diagnostics Centers

5.3. Academic and Research Institute

6. Biochips Industry - Regional Outlook

6.1. North America

6.1.1. Market By Type

6.1.2. Market By Substrate Material

6.1.3. Market By End User

6.1.4. Country Analysis

6.1.4.1. United States

6.1.4.2. Canada

6.2. Europe

6.3. Asia-Pacific

6.4. Latin America

6.5. Middle East and Africa

7. Competitive Landscape

7.1. Agilent Technology Inc.

7.2. Biochain Institute Inc.

7.3. bioMerieux S.A.

7.4. Bio-Rad Laboratories Inc.

7.5. Cepheid Inc.

7.6. Cybrdi Inc.

7.7. Fluidigm Corporation

7.8. Gamida For Life Group

7.9. Illumina Inc.

7.10. Imgenex

7.11. Merck GmbH

7.12. Origene Technologies Inc.

7.13. Perkinelmer Inc.

7.14. Samsung Electronics Inc.

7.15. Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/6r9ev


These press releases may also interest you

at 21:25
NorthWest Healthcare Properties Real Estate Investment Trust (the "REIT") , Canada's leading global diversified healthcare real estate investment trust, today announced its results for the three months ended September 30, 2019. Commenting on the...

at 21:15
Rights4Vapers.com, the country's leading vaping consumer rights organization, is discouraged and dismayed by the B.C. government's proposed vaping regulations. "As the voice of Canadian adult vapers, we have to ask why...

at 21:05
Shionogi & Co., Ltd. (hereafter "Shionogi") today announced the U.S. Food and Drug Administration (FDA) has approved FETROJA® (cefiderocol) for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment...

at 20:17
FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics Contract Development and Manufacturing Organization (CDMO) has announced the expansion of its gene therapy services with the addition of dedicated process and analytical development...

at 20:00
Kaden, the digital behavioral health company (formerly known as Thrivee), announced today its commitment to address the opioid addiction crisis in New Hampshire. The company is exploring a collaborative effort with Catholic Medical Center (CMC) to...

at 19:00
With Giving Tuesday on Dec. 3, 2019, the Veterans Affairs (VA) Maryland Health Care System reminds community members, businesses and organizations about the benefits of supporting local hospitalized veterans throughout Maryland. Created in 2012,...



News published on 18 july 2019 at 10:55 and distributed by: